Stuart Schnitt on the future of breast pathology with the potential benefits of AI

Sara Tolaney shared on X:

“Dr Stuart Schnitt does an outstanding job highlighting the future of breast pathology with the potential benefits of AI (and told us he’d like an augmented microscope with real-time AI for his birthday!)”

Source: Sara Tolaney/X

Sara Tolaney is the Chief of the Division of Breast Oncology at Dana-Farber Cancer Institute. She also serves as Associate Director of the Susan F. Smith Center for Women’s Cancers and is a Senior Physician at Dana-Farber Cancer Institute and Associate Professor of Medicine at Harvard Medical School.

Her research focuses on the development of novel therapies in the treatment of breast cancer and developing more effective and less toxic treatment approaches. Her work has demonstrated that a relatively low-risk regimen is beneficial in women with early-stage node-negative HER2-positive cancers, and this works has been incorporated into national and international guidelines.